Abstract

FORMULATION DEVELOPMENT AND EVALUATION OF EMULGEL DRUG DELIVERY SYSTEM FOR THE TREATMENT OF PSORIASIS

Monesh Patil*, Rahul Sharma, Dr. Jagdish Chandra Rathi

Abstract

Mometasone furoate (MF) is a topical glucocorticoid having antiinflammatory, anti-pruritic, anti-hyper proliferative activity. Owing to these properties it is recommended in chronic inflammation and psoriasis. In market, MF cream and lotion (0.1%) are available, which show slight skin irritation, burning and common side-effects due to steroids. To overcome the shortcomings of conventional formulations, there is a need to develop a novel formulation that can reduce these side-effects and show maximum desired effects. Thus, Emulgel can be prepared which would help in increasing skin deposition as well as provide sustained release. Developed formulations of Mometasone furoate were evaluated for the physiochemical parameters such as drug content, viscosity, spreadability, in vitro diffusion. Viscosity studies of various formulations revealed that formulation F4 is better compare to others. Release of drug from Mometasone furoate emulgel was significantly slower, which confirmed that slight prolonged drug release rate. Incorporation of carbomer affected the release rate of the drug. By increasing the amount of carbomer, the release rate of the drug decreased, which could be related to the increased rigidity of the formulation, followed by its decreased permeability for the drug. In vitro drug release from the semisolid preparation of Mometasone furoate emulgel optimized formulation F4 shows significantly improved in drug release rate as compare to marketed preparation.

Keywords: Psoriasis, Formulation development, Carbopol 940, Mometasone furoate, Emulgel, In vitro drug release.